Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
A phase 3 trial of Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin / leuprolide, Histrelin, Leuprolide, Relugolix and Triptorelin in Prostate cancer, run by NRG Oncology, active and no longer recruiting.
Overview
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial is a phase 3 interventional study registered as NCT04513717 by NRG Oncology, with 2753 participants planned, started 2021-01-21 and due to reach its primary completion in 2033-12-31. Interventions recorded: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin. Conditions recorded: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8.
Linked to the drug Buserelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialRadiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Shares Buserelin, Flutamide, Degarelix, Triptorelin and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Histrelin, Flutamide, Degarelix, Triptorelin and the tag pipeline.
- TrialTreating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Shares Relugolix, Degarelix, Triptorelin, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialProstate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Shares Buserelin, Flutamide, Triptorelin, Bicalutamide and the tag pipeline.
- TrialAssessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Shares Relugolix, Degarelix, Triptorelin, Bicalutamide and the tag pipeline.
- TrialHormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialHormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialFlutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.